Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:23 AM
Ignite Modification Date:
2025-12-25 @ 3:23 AM
NCT ID:
NCT00000905
Eligibility Criteria:
Inclusion Criteria
You may be eligible for this study if you:
* Are HIV-positive.
* Have a CD4 count greater than 100 cells/mm3.
* Have healed CMV retinitis after receiving anti-CMV therapy for at least 8 weeks within 3 months prior to study entry.
* Have taken antiretroviral therapy for at least 8 weeks prior to study entry; combination therapy must include at least 2 of the following: protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), or non-nucleoside reverse transcriptase inhibitors (NNRTIs).
* Have a life expectancy of at least 6 months.
* Are at least 13 years old (need consent if under 18).
Exclusion Criteria
You will not be eligible for this study if you:
* Have any unstable or severe medical conditions that would keep you from completing the study.
* Require chemotherapy or radiation therapy.
* Have a history of certain eye disorders.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
13 Years
Study:
NCT00000905
Study Brief:
Protocol Section:
NCT00000905